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To assess the influence of the 2012 USPSTF recommendation against PSA-based 
screening on oncological and functional outcomes following RALP. 
Materials and methods: - 
We retrospectively analyzed patients that underwent RALP between 2008-2018 with 
a minimum of 12 months follow up from a prospectively collected IRB approved 
database. The impact USPSTF statement against PSA screening on our surgical 
outcomes was assessed using a logistic regression model using two groups indicating 
patients treated before/after the USPSTF statement and time trends for each 
successive year. 
Results:- 
The mean preoperative PSA increased from 6.0 to 7.4 ng/ml after the USPSTF 
recommendations. We detected statistically significant time-trend changes after 2012 
including an increase in the positive slope of Gleason ≥3+4 or ≥pT3.  We detected a 
fall in bilateral FNS and increase in PNS. Total PSM rate after the USPSTF 
recommendation increased. However, PSM rates pertinent to each pathological stage 
did not change significantly after 2012. There was a significant negative trend change 
in the postoperative 12-month continence and potency indicating a breakpoint in 
functional outcomes after 2012. We detected a 1.7 fold increase in 12-month BCR 
rates. The 12-month BCR, potency and continence rates were maintained in young 
(<55 years) patients with SHIM>22 and low volume disease.  
 
Conclusion: -  
 Since the USPSTF’s recommendation in 2012, we have seen a significant 
increase in the incidence of the high-risk disease that has forced us to modify our 
approach to the procedure and the grade of NS leading to a wider resection to maintain 
the PSM has led to a decrease in postoperative functional recovery. Patients with good 
characteristics have performed well before and after the USPSTF’s recommendation, 
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Introduction:  
The advent of PSA screening in the early 1980s led to a significant increase in 
the overall diagnosis of prostate cancer (PCa) and subsequently a decrease in the rate 
of PCa mortality. (1)  Over the last 2 decades, this has amounted to an earlier diagnosis 
of the disease and; therefore, to a reduction of approximately 25% in mortality for PCa 
in patients who were screened at least once in their lifetime(1).  PCa is currently the 
most commonly diagnosed solid organ tumor in males and the second leading cause of 
cancer death with an estimated 31,620 deaths this year in the US. (2) Since the late 
1980’s PSA based screening for PCa has become routine and part of a normal men’s 
yearly examination. (3)  However, in 2012 the US preventive task force (USPSTF), the 
governmental body that advises and guides primary care physicians regarding basic 
screening, proposed a “D” recommendation for PCa screening. This recommendation 
basically recommended against all PSA based routine screening in all men of any age, 
ethnicity or family history. The rationale for this recommendation is that a significant 
number of patients were being over diagnosed and over treated for PCa, and the 
perceived lack of data supporting survival advantages from PSA screening(4).  This 
decision was obviously controversial and is currently still debated. 
The USPSTFs recommendation against PSA screening has had some profound 
effects as it led to the reduced utility of PSA by primary physicians and physicians in 
general. The PSA utility decreased 39% and PCa biopsy rate decreased by 30%(5,6) 










This article is protected by copyright. All rights reserved 
falling from 17.5 per month to 10 males per month following this recommendation. (7)  
This has also led to the delay in the diagnosis of some men with PCa with significant 
disease. Ahlering et al recently reported a significant fall in Gleason Score (GS) 6 and 
increase in ≥ GS 4+4 by 24%, The 1-year Biochemical Recurrence (BCR) rate rose 
from 6.2 to 17.5%(8) 
Our group recently published an article showing the changing trends in the PCa 
characteristics of our patients as a result of the USPSTF guided changes in PSA 
screening. Considering the changes in screening guidelines and referral patterns, we 
investigated the time trends in the patient’s surgical and pathological characteristics 
before and after the recommendation (9,10).  The analysis showed an increase in 
intermediate and high-risk PCa, with a demonstrable breakpoint following the USPSTF’s 
recommendation (9). The current study assesses the impact of the changing landscape 
of PSA screening and PCa diagnosis on functional and oncological outcomes of 
patients that undergo surgical treatment with robot-assisted laparoscopic prostatectomy 
(RALP) in a single surgeon practice with a decade of experience.   
 
Materials and methods:  
We retrospectively analyzed all patients who underwent RALP between January 
2008 to March 2018 from a prospectively collected IRB approved PCa database. After 
excluding patients who underwent salvage prostatectomy, 8,564 out of 10,409 patients 
with a minimum of 12 months follow up were available for analysis. The patients were 
then divided into two primary groups, from January 2008 to December 2012 (Group 1) 
and from January 2013 to March 2018 (Group 2). All patient referrals to us for up to 6 
months after the USPSTF recommendations in 2012 were included in Group 1. The 
time frame for each group was decided upon the lag time for the screening 
recommendations to start changing clinical practice patterns in our referral community, 
and the delay from cancer diagnosis to scheduling surgery. These patients were then 
subjected to trend analysis for each year by comparing their oncological and functional 
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All patients underwent a 6-port transperitoneal RALP technique developed at our 
institution and all surgeries were performed by a single surgeon (11). Nerve-sparing 
(NS) was performed athermally with a modified, early retrograde release of the 
neurovascular bundle (NVB)(12). The quality of NVB preservation in each side was 
graded by the surgeon prospectively at the termination of RALP based on a 5-point NS 
grading system that was developed by our group(13). To perform descriptive and 
comparative analyses, the degree of NS was categorized into four groups based on the 
total score of both sides as described previously by our group(9) Bilateral standard 
pelvic lymph node dissection (PLND) was performed in patients classified as 
intermediate or high-risk, based on the D’Amico classification (14,15). 
 
Post-operative care and follow-up: 
Immediate post-operative complications were evaluated using the Clavien-Dindo 
grading system(16). The histopathological data of all patients were derived from the 
database and all specimens were processed by the same team of pathologists using 
the AJCC TNM staging system, GS, and the presence of positive surgical margins 
(PSM) (17). Follow-up data were prospectively collected at a regular interval (quarterly 
for the first year and then semiannually thereafter) using validated questionnaires like 
EPIC, SHIM  and serum PSA levels to assess the BCR. All data were entered into the 
database and regularly updated by a dedicated research team by reviewing patients’ 
follow-up charts and conducting regular phone calls. 
Definition of functional outcomes: 
Continence was defined as the usage of no pads. Potency was defined as the 
ability to penetrate and satisfactorily complete intercourse with or without PDE5 
inhibitors in more than half of the attempts ( scores more than 3 in questions 2 and 5 in 
SHIM).BCR was defined as two consecutive PSA levels of > 0.2 ng/ml(18). Continence, 
potency, and BCR status at postoperative 12 months were included in the trifecta. 
Additionally, complications occurring either during or within 90 days of surgery, and the 
presence of a PSM were included in the postoperative pentafecta(16,19). 
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Continuous variables were reported as median values (interquartile range-IQR) 
or as mean±standard deviation (SD) and were compared across independent groups by 
the Wilcoxon rank-sum test. Categorical variables were summarized as absolute and 
relative percent frequencies, and the chi-squared test was performed to compare their 
distribution across the two study groups. A subgroup analysis was performed by further 
categorizing the patients based on age, preoperative PCa risk class, and baseline 
sexual function, and their postoperative 12-month oncological and functional outcomes 
were compared between the pre- and post-USPSTF recommendation groups (Groups 1 
and 2, respectively). 
In order to detect the impact USPSTF statement against PSA screening on our 
functional and oncological outcomes, time-trend changes were investigated for these 
variables using a logistic regression model with two covariates and their interactions; 
the time numerical covariate designated for each successive year from 2008 to 2018, 
and a binary variable indicating patients treated before or after the USPSTF statement 
(ie. Groups 1 and 2, respectively). The likelihood-ratio (LR) test was used to test 
differences in the trend slopes and intercepts in Groups 1 and 2. A breakpoint was 
identified between the groups if the LR test showed a significant difference between the 
intercepts and/or slopes of the two linear trends. Statistical analyses were performed 
using SPSS 25 (IBM Corp, Chicago IL), Stata 15 (StataCorp 2017, College Station, TX), 
and R 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) software. A p-
value of less than 0.05 was considered statistically significant.  
 
Results:  
Baseline patient characteristics:  
A total of 8,564 patients with at least 12 months follow up were analyzed (Table 
1). Overall, 37.9%, 44.6%, and 18% of patients had D’Amico low-, intermediate-, and 
high-risk disease, respectively. The mean preoperative PSA increased from 6.0 to 7.4 
ng/ml after the USPSTF recommendations. There was also a 19% increase in the 
incidence of intermediate- and high-risk disease. Baseline sexual function was not 
significantly different before and after the 2012 statement. (Table 1)  
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Table 2 summarizes the perioperative and pathological characteristics before 
and after the 2012 USPSTF recommendations. We detected a 17% decrease in 
bilateral full (grade 1) NS and a 19% increase in partial (grades 2 and 3) NS after the 
USPSTF statement. Our non-organ confined disease (≥pT3) rates increased from 
23.3% to 39%, a 1.7 fold increase and pathological GS ≥8 rates were doubled from 
8.1% to 15.5%, a 1.9  fold increase (p<0.001, Table 2). There was a significant increase 
in the slope of the positive time-trend of GS>=3+4 or ≥pT3 disease rate after the end of 
2012 (Figure 1a), indicating an association between the rise in the incidence of clinically 
significant disease and the USPSTF recommendation. 
Overall, the positive surgical margins (PSM) rate was 16.7%. The total PSM rate 
increased from 14.1% to 18.9%, a 1.3 fold increase after the USPSTF recommendation 
(p<0.001). However, PSM rates pertinent to each pathological stage did not change 
significantly after the 2012 recommendation (Table 2). Our time-trend analyses also did 
not show any significant changes in the PSM time-trend after the 2012 USPSTF 
statement.  
Oncological outcomes: 
In the entire cohort, 4.3% of patients had PSA persistence and 10.8% had PSA 
recurrence at a median follow-up of 49 months (range: 12 to 137 months). We detected 
an increase in 12-month BCR rates from 2.4% to 4.2%, a 1.7 fold increase after the 
2012 USPSTF recommendation (p<0.001). However, when subsets of patients based 
on age, PCa risk group, and baseline sexual function were examined, there were no 
differences between pre- and post-recommendation 12-month BCR across all patient 
groups (Table 3). Likewise, our logistic regression analyses did not demonstrate any 
significant changes in the time trends for 12-month BCR rates after the USPSTF 
recommendation (Figure 1 and Table 4).  
 Functional outcomes:  
Overall, 90.6% of patients achieved full (pad free) continence. In Group 1, the 
continence rate was 94.3% and in group 2 it was 87.5 % (p<0.001). The median time to 
achieve continence was not different between the two groups (46 vs. 45 days). We 
detected a significant increase in the negative slope of postoperative 12-month 
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recommendation (Table 4), indicating a breakpoint in continence recovery at the end of 
2012 (Figure 1a).   
The Overall potency rate at postoperative follow-up was 56.4%, irrespective of 
age, pre-operative SHIM score, and NS status. The Overall potency rate in group 1 was 
65.6% as compared to 48.6% in group 2 (p<0.001), indicating a significant decline after 
the USPSTF statement. Our sub-group analysis revealed that 12-month potency and 
continence rates were maintained in young (<55 years) patients with good preoperative 
sexual function (SHIM>=22) and low volume disease. Following the recommendation, 
the subgroup with age < 55 yrs, SHIM >= 22 and D’Amico class 1 dropped from 60.1% 
to 39.9%. In this sub-group, pre- and post-recommendation potency rates were 93% vs. 
88.7% in D’Amico class 1, and 88.9% vs.83% in D’Amico class 2 patients, respectively 
(p>0.05 for all comparisons, Table 3). In all other patient subsets, 12-month potency 
and continence rates showed a statistically significant decline after the USPSTF 
recommendation (Table 3). The worst outcomes were observed in patients >65 years 
with D’Amico high-risk cancer, in which the 12-month potency rate was 60% before vs. 
36% after the USPSTF recommendation (p=0.005, Table 3).  The outcomes were 
significantly correlated to disease status, the more advanced disease states resulted in 
poorer outcomes.   
In line with continence and potency outcomes, there was a statistically significant 
decrease in our 12-month trifecta and pentafecta rates from 55.1% to 41.7%, and 
49.1% to 36.6%, respectively, after the USPSTF statement (p<0.001 for both 
comparisons, Table 2). We also detected significant changes in the negative time-
trends of postoperative 12-month trifecta and pentafecta after 2012 (Figure 1b, Table 4-
), confirming an association between the decline in our trifecta/pentafecta outcomes and 
the USPSTF recommendation.  
 
Discussion:  
Historically, PSA has been a widely accepted screening tool for the detection of 
PCa (20,21). In 2012, the USPSTF recommended against the practice of using PSA for 
routine screening of PCa in all age groups. The rationale for this recommendation was 
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PCa (4). However, the USPSTF’s recommendation had widespread implications, 
resulting in a significant fall in the number of patients being referred with high PSA, and 
a significant decrease in the number of patients undergoing prostate biopsy in the 
subsequent years (7,22–24). Studies have further demonstrated that patients 
undergoing biopsy after 2012 had a higher GS and more positive cores. (5,25).These 
findings were also confirmed in our study. Specifically, there was a 1.3 fold increase in 
intermediate and a 1.7- fold increase in high-risk patients undergoing RALP after 2012. 
There was also a 1.7-fold increase in ≥pT3 disease following the recommendations 
(p<0.001).Although the GS>=3+4 or ≥pT3 were increasing prior to the recommendation 
due to factors like increased active surveillance of low-risk group and increased 
utilization of RALP,there was a significant time-trend change in high-risk disease 
following the recommendation ( Fig.1)(26,27) 
Changes in PCa characteristics after the 2012 USPSTF recommendation have 
led to significant changes in RALP practice. In a recent study, our group reported data 
showing a rise in aggressive cancer features was associated with a significant decline in 
our bilateral full NS performance and a significant increase in our partial NS rates, to 
maintain our PSM rates (9). A breakpoint was detected in the time-trends of these NS 
grades at the end of 2012, suggesting an association between the changes in our NS 
performance and the USPSTF statement. In the present study, we have further 
analyzed the functional and oncological implications of these changes in our clinical 
practice. 
We noted that our PSM rates pertinent to each pathological stage were 
maintained after the 2012 USPSTF recommendation as a result of increased 
performance of partial over bilateral full NS. Accordingly, our 12-month BCR rates 
showed a small but statistically significant increase from 2.4% to 4.2% a 1.7 fold change 
after the USPSTF recommendation. However, this significance was lost when short-
term BCR rates were examined in patient subgroups based on age and PCa risk 
groups. Ahlering et al. recently compared 4-year pre- vs. post-USPSTF statement RALP 
outcomes in 19,602 patients from nine high-volume referral centers in the United States 
and reported a 2.8 fold increase in 1-year BCR rates from 6.2% to 17.5% after the 
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probably related to the multi-center nature of their study and differences in the RALP 
technique. Also, extensive experience of our group helped us to adapt our surgery to 
maintain stage-wise PSM rate which is probably the best one can offer surgically and 
the change in 12-month BCR is due to the inherent character of the disease itself due to 
deferred screening. Nevertheless, long-term data is needed to better elucidate the 
impact of 2012 USPSTF recommendations on trends oncological outcomes after RALP.  
In our experience, the trade-off for compensating PSM and BCR rates with wider 
NVB dissection was a decrease in the functional recovery after RALP. In the entire 
cohort regardless of age, SHIM score or NS status, we found a significant decrease in 
full continence rates from 94% to 87.5%, and a significant decrease in potency rates 
from 66% to 49% after the USPSTF recommendation (p<0.001 for both comparisons). 
Our time-trend analysis demonstrated a significant breakpoint at the end of 2012, 
indicating an association between the decline in functional recovery and the task force’s 
PSA screening recommendation. The decrease in continence and potency rates was 
associated with a significant decrease in our 12-month trifecta and pentafecta rates, as 
evidenced by the decline in the time-trends of these variables after 2012. To our 
knowledge, this is the first study to investigate the impact of 2012 USPSTF 
recommendations on functional recovery and trifecta and pentafecta rates after RALP.  
In the present study, we performed a subgroup analysis to investigate the 
changes in functional and oncologic outcomes in different patient groups based on age 
and PCa risk class. Interestingly, the 12-month continence, potency, and BCR rates did 
not change significantly after the USPSTF recommendation in patients <55 years with 
D’Amico low- to intermediate-risk disease and a preoperative SHIM score>=22. Of note, 
the best postoperative outcomes were achieved in these patients. This suggests that 
our surgical technique was stable in the “ideal patient” with young age and low-volume 
disease, and the functional outcomes were less likely to be affected by changing cancer 
characteristics, leading to maintained high continence and potency recovery rates. In all 
other patient sub-groups, our functional recovery rates deteriorated after 2012, possibly 
due to the increasingly lower performance of high-quality NS in a growing population of 
patients with high-risk disease, or due to the higher age which may not compensate for 










This article is protected by copyright. All rights reserved 
Despite reporting novel information, the present study has some limitations that 
need to be addressed. First, our study has the inherent limitations of a retrospective 
analysis. However, our IRB approved, and prospectively maintained database ensures 
the quality of clinicopathological and follow-up data. Second, as a high-volume tertiary 
referral center treating increasingly more complex patients, our results may not be 
generalizable to other centers. Third, using a time-trend analysis may not account for all 
possible confounding factors and establish a direct cause/effect relationship. However, 
it can demonstrate a potential association between a factor and the outcome. Fourth, 
the length of our follow up, especially in the post-recommendation group, was not 
enough to draw final conclusions regarding the changes in long-term oncologic 
outcomes. Despite its limitations, this is the first study to analyze the effect of USPSTF’s 
2012 recommendations against PSA screening on both oncological and functional 
robotic prostatectomy outcomes.  
 
Conclusion:  
Comparing the characteristics of prostate cancer patients before and after the 
USPSTF’s “D” recommendation for PSA screening in 2012, we have seen a significant 
increase in the incidence of the high-risk disease being treated in our practice. These 
changes have forced us to modify our approach to the procedure and the grade of NS.  
The wider resection and decreased amount of NS in order to maintain the PSM had led 
to a decrease in postoperative functional recovery. Patients with good characteristics 
have performed well before and after the USPSTF’s recommendation, implying that the 
quality of surgery did not change over time. These results may suggest a benefit from 
earlier PSA screening in terms of maintaining high functional recovery rates in patients 
who are candidates for robotic prostatectomy. Further long-term studies are essential to 
investigate the pragmatic effect of this PSA recommendation throughout the community 
and PSA screening should be considered until an ideal screening tool is developed. 
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Table 1 – Comparison of preoperative characteristics of the patient prior to and after the 
recommendations.  
Parameters Total 
January 2008  
to  
December 2012 




Total 8564(%) 3954(%) 4610(%)  
Age (mean±SD) 61.66(7.6) 60.87(7.6) 62.33(7.6)          < 0.001 
Age (years)     
 
         < 0.001 
Less than 55 1854(21.6) 885(19.2) 969(24.5) 
55 – 65 3756(43.9) 1958(42.5) 1797(45.4) 
More than 65 2954(34.5) 1766(38.3) 1188(30) 
BMI (mean±SD) 28.32(4.2) 28.15(4.1) 28.46(4.3) .001 
BMI (kg/m2)    .004 
 Less than 30 6068(70.9) 3206(69.5) 2862(72.4) 
30 and above 2496(29.1) 1092(27.6) 1404(16.4) 
D’Amico score     
 
< 0.001 
Low risk 3228(37.9) 1895(48.1) 1333(29) 
Intermediate risk 3800(44.6) 1532(38.9) 2268(49.4) 
High Risk 1536(18) 511(13) 1025(21.9) 
PSA (mean±SD) 6.76(8.82) 5.97(4.79) 7.44(11.13) < 0.001 
Pre-op PSA (ng/dl)     
 
< 0.001 
Less than 10 7466(87.2) 3585(90.7) 3881(84.2) 
10-20 887(10.4) 302(7.6) 585(12.7) 
More than 20 211(2.5) 67(1.7) 144(3.1) 
Preop SHIM 
(mean±SD) 
18.03(7.6) 18.36(7.5) 17.75(7.74)               .062 
Preop AUA 
(mean±SD) 









January 2008  
to 
 December 2012 
N= 3954 (%) 
January 2013  
to 
 March 2018 n= 
4610 (%) 
P Value 
Median (IQR) operative time (minutes)  122.5 (25.6) 126.1 (26.5) 117.9 (22.04) <0.001 
Median (IQR) console time (minutes) 76.9 (10.7) 79.5 (10.9) 76.2 (10.15) <0.001 
Median (IQR) estimated blood loss (ml) 118.2 (84.7) 134.5 (97.96) 100.0 (62.4) <0.001 
Nerve Sparing        <0.001 
           Bilateral Full NS (Grade 1) 3830(46) 2046(55.1) 1784(38.7) 
           High-grade Partial NS (Grade 2)  2810(33.8) 993(26.7) 1817(39.4) 
           Low-grade Partial NS (Grade 3)  1060(12.7) 364(9.8) 696(15.1) 
           Poor NS (Grade 4)  625(7.5) 312(8.4) 313(6.8) 
Pathological stage    <0.001 
Organ confined (≤ pT2c) 5842(68.2) 3033(76.7) 2809(61) 
Extra prostatic extension (pT3a) 1929(22.5) 651(16.5) 1278(27.7) 
Seminal vesicle invasion (pT3b) 676(7.9) 236(6) 440(9.5) 
Adjacent organ involved (pT4) 117(1.4) 34(0.9) 83(1.8) 
Pathological Node Positive 236 (2.7) 43(1.08) 193(4.1) <0.001 
Pathological Gleason score    <0.001 
6 2158(25.5) 1303(33.2) 855(18.8)  
7 5824(62.4) 2305(58.7) 2979(65.6)  
≥ 8 1024(12.1) 319 (8.1) 705(15.5)  
Positive Surgical Margin 









In organ confined disease(pT2) 524(9) 264(8.8) 260(9.3) .469 
In Extra-prostatic extension (pT3a) 499(25.9) 169(26) 330(25.8)      .948 
In seminal vesicle invasion (pT3b) 291(43) 93(39.4) 198(45) .162 
(pT4) 114(97.4) 32(94.1) 82(98.8)      .446 
Median-Follow up (months)  49(59) 84(40) 36 (29)  
Continence 7762(90.6) 3730(94.3) 4032(87.5) <0.001 
Days to continence (Median(IQR)) 46 (62) 46 (59) 45 (80)  
Potency achieved (Irrespective of Age, 
Pre-op potency and NS) 
4833(56.4) 2593(65.6) 2240(48.6) <0.001 
Days to potency (Median (IQR)) 91 (224) 82 (169) 97 (240.5)  
PSA persistence  370(4.3) 134(3.4) 236(5.1) <0.001 
BCR at 12 months  288(3.4) 96(2.4) 192(4.2) <0.001 
Trifecta achieved 4100(47.9) 2179(55.1) 1921(41.7) <0.001 
Pentafecta achieved 3583(41.8) 1941(49.1) 1642(36.6) <0.001 
 
 
Table No 3: Comparison of outcomes before and after the recommendation sub stratified 












































Age less than 55, 
SHIM>= 22 and D 



















Age less than 55, 
SHIM>= 22 and D 



















Age less than 55, 
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years, SHIM>= 22 and 
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SHIM>= 22 and D 
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Table 4: - Time trends changes in outcomes following the 2012 USPSTF statement - the 
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Figure 1A - Trend change analysis in functional outcomes and oncological parameters 
(logit scale) following the 2012 USPSTF statement for patients undergoing surgery at 12 























Figure 1B - Trend change analysis in outcomes (logit scale) following the 2012 USPSTF 
statement for patients undergoing surgery at 12 months 
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